@article{b60c76d7cb844de6bce873a5862fd602,
title = "Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial",
keywords = "beam, bortezomib, cytarabine, high-dose cytarabine, immunochemotherapy, maintenance therapy, mantle cell lymphoma, mcl younger, multicenter, nordic mcl2, phase ii trial, randomised, rescue, rituximab, survival, SURVIVAL, IMMUNOCHEMOTHERAPY, RITUXIMAB, NORDIC MCL2, MCL YOUNGER, MULTICENTER, HIGH-DOSE CYTARABINE, BEAM, RESCUE, Mantle cell lymphoma, phase II trial",
author = "J.K. Doorduijn and J.M. Zijlstra and P.J. Lugtenburg and M.J. Kersten and L.H. Bohmer and M.C. Minnema and M.A. MacKenzie and R.V. Kooij and {de Jongh}, E. and T.J.F. Snijders and {de Weerdt}, O. and {van Gelder}, M. and M. Hoogendoorn and R.B.L. Leys and R.E. Kibbelaar and {de Jong}, D. and D.A. Chitu and {Van't Veer}, M.B. and H.C. Kluin-Nelemans",
year = "2020",
month = aug,
day = "1",
doi = "10.1111/bjh.16567",
language = "English",
volume = "190",
pages = "385--393",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley",
number = "3",
}